Obesity, MorbidNCT07008274
Laparoscopic Sleeve Gastrectomy-Induced Decline in Plasma Asprosin and Its Association With Metabolic Recovery
An observational study of Obesity, Morbid, run by Northern Jiangsu People's Hospital at 1 site in China.
Trial summary
the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR)… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Obesity, Morbid
- What is being tested?
- surgery
- Type of treatment
- Surgery or procedure
- How many people
- 85 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2021to 31 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Adults with obesity (BMI ≥37.5 kg/m², or ≥32.5 kg/m² with metabolic comorbidities such as type 2 diabetes, hypertension, or dyslipidemia), aged 18-65 years, undergoing laparoscopic sleeve gastrectomy at a single tertiary hospital in China. Healthy normal-weight controls (BMI 18.5-23.9 kg/m²) without metabolic disorders were also recruited for baseline comparison.
Who may be able to join
- age between 18 and 65 years;
- body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity;
- availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.
Who cannot join
- history of prior bariatric or gastrointestinal surgery;
- active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction;
- pregnancy during the study period;
- incomplete clinical or biochemical data.
Trial locations and contacts
1 site in 1 country.
About this study
the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.
- Conditions
- Obesity, Morbid
- Being tested
- surgery
- Keywords
- bariatric surgery, asprosin
- Medical subject headings
- Obesity, Morbid, Arachnodactyly
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
surgeryProcedure or surgery
laparoscopic sleeve gastrectomy
| Study group | Role | What they receive |
|---|---|---|
| surgery | surgery Receives: Procedure: surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma asprosin levels at 3, 6, and 12 months
Measured: 1 year
Secondary outcomes (1)
BMI at 3, 6, and 12 months
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start1 Jan 2021
- Primary completion31 Jan 2025
- Study completion31 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obesity, MorbidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Retrospective
- Enrolment
- 85 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northern Jiangsu People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daorong Wang, Northern Jiangsu People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07008274
- Sponsor's protocol ID
- NorthernJiangsu123
- Status last verified
- Jun 2025
- First submitted
- 11 May 2025
- Last updated
- 6 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhao S, Fu Y, Ding Z, Zi M, Wang J, Zhou J, Li R, Wang W, Wang D. Sleeve gastrectomy induces adipose browning via suppression of Asprosin and activation of the ATF3-Nrf2/HO-1 axis. Int J Obes (Lond). 2026 Jul 17. doi: 10.1038/s41366-026-02167-3. Online ahead of print.
PubMed 42469432
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Laparoscopic Sleeve Gastrectomy-Induced Decline in Plasma Asprosin and Its Association With Metabolic Recovery
- ClinicalTrials.gov ID
- NCT07008274
- Acronym / sponsor ID
- NorthernJiangsu123
- Conditions
- Obesity, Morbid
- Keywords
- bariatric surgery, asprosin
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 85 participants (actual)
- Lead sponsor
- Northern Jiangsu People's HospitalUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 31 Jan 2025 (actual)
- Study completion
- 31 Jan 2025 (actual)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.
Study design
- Observational model
- Case crossover
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| surgery | – | Procedure: surgerysurgery |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adults with obesity (BMI ≥37.5 kg/m², or ≥32.5 kg/m² with metabolic comorbidities such as type 2 diabetes, hypertension, or dyslipidemia), aged 18-65 years, undergoing laparoscopic sleeve gastrectomy at a single tertiary hospital in China. Healthy normal-weight controls (BMI 18.5-23.9 kg/m²) without metabolic disorders were also recruited for baseline comparison.
Key inclusion criteria (3 listed)
- age between 18 and 65 years;
- body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity;
- availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.
Key exclusion criteria (4 listed)
- history of prior bariatric or gastrointestinal surgery;
- active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction;
- pregnancy during the study period;
- incomplete clinical or biochemical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| surgerylaparoscopic sleeve gastrectomy | Procedure or surgery | surgery |
Primary outcome
Plasma asprosin levels at 3, 6, and 12 months
Time frame: 1 year
1 secondary outcome
BMI at 3, 6, and 12 months
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2025.
- Derived from this study: PubMed 42469432Zhao S, Fu Y, Ding Z, Zi M, Wang J, Zhou J, Li R, Wang W, Wang D. Sleeve gastrectomy induces adipose browning via suppression of Asprosin and activation of the ATF3-Nrf2/HO-1 axis. Int J Obes (Lond). 2026 Jul 17. doi: 10.1038/s41366-026-02167-3. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Obesity, Morbid
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Enrolling by invitationObservational study
Bariatric Surgery Registry
Obesity, Morbid
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
Active, not recruiting
Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients
Obesity, Morbid, Eating Disorder Symptom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, Morbid, run by Northern Jiangsu People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma asprosin levels at 3, 6, and 12 months (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07008274, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.